Menu
  • Join
  • Login
  • Contact
 

Search abstracts


How therapeutic drug monitoring can help to personalise dosing of anti-tnf monoclonal antibodies in patients with chronic inflammatory diseases

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Presentation
  • By: VANDE CASTEELE, Niels (KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium)
  • Abstract:

    Therapeutic drug monitoring (TDM) of anti-tumour necrosis factor (anti-TNF) monoclonal antibodies with measurements of drug serum levels and anti-drug antibodies (ADA) holds the potential to further unravel how pharmacokinetics (PK) and immunogenicity influence disease activity and clinical (non-)response in rheumatoid arthritis and inflammatory..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses